Abstract

Background: although high-density lipoprotein has cardioprotective effects, the association between serum high-density lipoprotein cholesterol (HDL-C) and hypertension is poorly understood. Therefore, we investigated whether high and low concentrations of HDL-C are associated with high blood pressure (HBP) using a large healthcare dataset. Methods: in a community-based cross-sectional study of 1,493,152 Japanese people (830,669 men and 662,483 women) aged 40–74 years who underwent a health checkup, blood pressures automatically measured at healthcare center were investigated in nine HDL-C groups (20–110 mg/dL or over). Results: crude U-shaped relationship were observed between the nine HDL-C and blood pressures in both men and women. Logistic regression analysis showed left-to-right inverted J-shaped relationships between HDL-C and odds ratios for HBP (≥140/90 mmHg and/or pharmacotherapy), with lower limits of 90–99 mg/dL in both sexes, which were unchanged after adjusting for confounding factors. However, further adjustment for body mass index and serum triglyceride concentration revealed positive linear associations between HDL-C and HBP, although blunt U-shaped associations remained in nonalcohol drinkers. Conclusion: both low and extremely high HDL-C concentrations are associated with HBP. The former association might be dependent on excess fat mass concomitant with low HDL-C, whereas the latter association may be largely dependent on frequent alcohol consumption.

Highlights

  • High-density lipoprotein (HDL) is considered to have cardioprotective effects, which were confirmed repeatedly in molecular, cellular, animal, and human studies [1,2,3,4,5]

  • Individuals with a high serum HDL cholesterol (HDL-C) concentration are considered to be at a lower risk of cardiovascular disease (CVD) and mortality according to the concepts of “the higher, the better” and “longevity syndrome” [2,6,7]

  • We investigated the association between HDL-C concentrations and pharmacotherapy for hypertension, which was diagnosed considering home blood pressure independently of current blood pressure measured at the checkup

Read more

Summary

Introduction

High-density lipoprotein (HDL) is considered to have cardioprotective effects, which were confirmed repeatedly in molecular, cellular, animal, and human studies [1,2,3,4,5]. Increasing HDL-C with pharmacotherapy, including cholesteryl ester transfer protein (CETP) inhibitors, did not show protective effects against CVD and mortality [15,16,17,18]. Among the plausible causes of adverse reactions with CETP inhibitors (torcetrapib and evacetrapib), a slight increase in blood pressure [19,20] and vasoactive effects [21] were observed and possibly were considered as markers of profound adverse reactions due to neuroendocrine or vasomotor effects [15]. To date, the fundamental relationship between serum HDL-C concentration and blood pressure was poorly argued, probably because an inverse relationship was observed between serum

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.